+

WO2002044360A3 - Arginine deiminase modifiee - Google Patents

Arginine deiminase modifiee Download PDF

Info

Publication number
WO2002044360A3
WO2002044360A3 PCT/US2001/029184 US0129184W WO0244360A3 WO 2002044360 A3 WO2002044360 A3 WO 2002044360A3 US 0129184 W US0129184 W US 0129184W WO 0244360 A3 WO0244360 A3 WO 0244360A3
Authority
WO
WIPO (PCT)
Prior art keywords
arginine deiminase
modified arginine
methods
modified
treating
Prior art date
Application number
PCT/US2001/029184
Other languages
English (en)
Other versions
WO2002044360A2 (fr
Inventor
Mike A Clark
Original Assignee
Phoenix Pharmacologics Inc
Mike A Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/723,546 external-priority patent/US6737259B1/en
Application filed by Phoenix Pharmacologics Inc, Mike A Clark filed Critical Phoenix Pharmacologics Inc
Priority to AU2001289132A priority Critical patent/AU2001289132A1/en
Priority to KR10-2003-7007054A priority patent/KR20040004449A/ko
Priority to CA002430077A priority patent/CA2430077A1/fr
Priority to EP01968928A priority patent/EP1337630A2/fr
Priority to JP2002546708A priority patent/JP2004515232A/ja
Publication of WO2002044360A2 publication Critical patent/WO2002044360A2/fr
Publication of WO2002044360A3 publication Critical patent/WO2002044360A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une arginine déiminase modifiée avec du glycol polyéthylénique, des méthodes de traitement du cancer, et des méthodes de traitement et/ou d'inhibition de métastase.
PCT/US2001/029184 2000-11-28 2001-09-19 Arginine deiminase modifiee WO2002044360A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001289132A AU2001289132A1 (en) 2000-11-28 2001-09-19 Modified arginine deiminase
KR10-2003-7007054A KR20040004449A (ko) 2000-11-28 2001-09-19 변형된 아르기닌 데이미나제
CA002430077A CA2430077A1 (fr) 2000-11-28 2001-09-19 Arginine deiminase modifiee
EP01968928A EP1337630A2 (fr) 2000-11-28 2001-09-19 Arginine deiminase modifiee
JP2002546708A JP2004515232A (ja) 2000-11-28 2001-09-19 修飾されたアルギニンデイミナーゼ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/723,546 2000-11-28
US09/723,546 US6737259B1 (en) 1997-05-12 2000-11-28 Modified arginine deiminase

Publications (2)

Publication Number Publication Date
WO2002044360A2 WO2002044360A2 (fr) 2002-06-06
WO2002044360A3 true WO2002044360A3 (fr) 2002-12-19

Family

ID=24906720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029184 WO2002044360A2 (fr) 2000-11-28 2001-09-19 Arginine deiminase modifiee

Country Status (7)

Country Link
EP (1) EP1337630A2 (fr)
JP (1) JP2004515232A (fr)
KR (1) KR20040004449A (fr)
CN (1) CN1518595A (fr)
AU (1) AU2001289132A1 (fr)
CA (1) CA2430077A1 (fr)
WO (1) WO2002044360A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250371B2 (en) * 2002-06-20 2009-01-29 Bio-Cancer Treatment International Limited Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
AU2003282883B2 (en) * 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
US9085659B2 (en) 2004-05-03 2015-07-21 Nektar Therapeutics Polymer derivatives comprising an imide branching point
WO2006015512A1 (fr) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Arginine déiminase modifiée
FR2884717B1 (fr) * 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) * 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN101812438B (zh) * 2010-03-25 2014-08-27 江苏泰康生物医药有限公司 一种精氨酸脱亚氨酶突变体及其制备与应用
CN102703339B (zh) * 2011-08-29 2013-08-14 山东恩贝生物工程有限公司 高产精氨酸脱亚胺酶菌株及用它生产l-瓜氨酸的方法
EP3782653B1 (fr) 2012-04-04 2025-03-19 Polaris Group Composition comprenant de l'arginine déiminase pégylée
KR102455753B1 (ko) 2013-03-15 2022-10-17 티디더블유 그룹 암치료를 위한 ａｄｉ-ｐｅｇ 20 항체에 대해 감소된 교차반응성을 지니는 아르기닌 탈이민효소
US10463721B2 (en) 2014-03-18 2019-11-05 Tdw Group Engineered chimeric pegylated ADI and methods of use
SG11201702103XA (en) 2014-09-16 2017-04-27 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
ES2905716T3 (es) * 2016-09-29 2022-04-11 Meharry Medical College Péptidos derivados de la arginina deiminasa de S. cristatus como inhibidores bacterianos
CN110121340B (zh) * 2016-11-02 2023-03-31 波拉里集团 聚乙二醇化精氨酸脱亚氨酶的调配物
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
CN106591270B (zh) * 2017-01-23 2018-09-21 江南大学 一株定点突变改造的基因工程精氨酸脱亚胺酶
BR112020010976A2 (pt) * 2017-11-30 2020-11-17 Jazz Pharmaceuticals Ireland Limited métodos de tratamento com asparaginase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04121187A (ja) * 1990-09-10 1992-04-22 Nikko Kyodo Co Ltd ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
WO1998051784A1 (fr) * 1997-05-12 1998-11-19 Phoenix Pharmacologics, Inc. Arginine deiminase modifiee
US6132713A (en) * 1997-01-31 2000-10-17 Enzon, Inc. Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04121187A (ja) * 1990-09-10 1992-04-22 Nikko Kyodo Co Ltd ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5372942A (en) * 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US6132713A (en) * 1997-01-31 2000-10-17 Enzon, Inc. Arginine deiminase derived from mycoplasma arthritidis and polymer conjugates containing the same
WO1998051784A1 (fr) * 1997-05-12 1998-11-19 Phoenix Pharmacologics, Inc. Arginine deiminase modifiee

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI, Hinxton, UK; 16 December 1997 (1997-12-16), FRASER, C ET AL.: "Borrelia burgdorferi (section 69 of 70) of the complete genome.", XP002211866, Database accession no. AE001183 *
DATABASE WPI Section Ch Week 200161, Derwent World Patents Index; Class A96, AN 1992-188063, XP002211867 *
KNODLER LEIGH A ET AL: "Cloning and expression of a prokaryotic enzyme, arginine deiminase, from a primitive eukaryote Giardia intestinalis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4470 - 4477, XP002211868, ISSN: 0021-9258 *
TAKAKU H ET AL: "Anti-tumor activity of arginine deiminase from mycoplasma arginini and its growth-inhibitory mechanism", JAPANESE JOURNAL OF CANCER RESEARCH, AMSTERDAM, NL, vol. 86, no. 9, 1 September 1995 (1995-09-01), pages 840 - 846, XP002092819 *
TAKAKU HARUO ET AL: "Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini.", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 84, no. 11, 1993, pages 1195 - 1200, XP008007607, ISSN: 0910-5050 *

Also Published As

Publication number Publication date
CN1518595A (zh) 2004-08-04
CA2430077A1 (fr) 2002-06-06
AU2001289132A1 (en) 2002-06-11
EP1337630A2 (fr) 2003-08-27
KR20040004449A (ko) 2004-01-13
WO2002044360A2 (fr) 2002-06-06
JP2004515232A (ja) 2004-05-27

Similar Documents

Publication Publication Date Title
EP0981607A4 (fr) Arginine deiminase modifiee
WO2002044360A3 (fr) Arginine deiminase modifiee
MXPA01006099A (es) Metodos y composiciones para reducir las permeabilidades de zonas subterraneas.
WO2002071928A3 (fr) Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
NO20015462L (no) Anvendelse av fthalazinderivater
AU2002312347A1 (en) Detection of ovarian cancer based upon alpha-haptoglobin levels
WO2004005472A3 (fr) Inhibiteurs de ftsz et leurs utilisations
WO2000004954A3 (fr) Nouveaux inhibiteurs d'urokinase
ZA200202816B (en) Modified plant viruses and methods of use thereof.
WO2002030465A3 (fr) Compositions inhibant la proliferation de cellules cancereuses
WO2005108565A3 (fr) Enzymes modifiees, procedes de production d'enzymes modifiees et utilisations de ces dernieres
WO2004058158A3 (fr) Traitement du cancer metastatique avec la sous-unite de la toxine de shiga
WO2001018542A3 (fr) Compositions, trousses et methodes pour l'identification, l'analyse, la prevention et la therapie du cancer des ovaires
WO2000053776A3 (fr) Nouveaux genes humains du type kallikreine
WO2001051523A3 (fr) Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2001005821A3 (fr) Utilisations de l'il-10 virale
WO2001042792A3 (fr) Compositions, kits, et methodes d'identification, d'evaluation, de prevention, et de therapie du cancer du col de l'uterus
WO2002046765A3 (fr) Compositions, trousses, et methodes d'identification, d'evaluation, de prevention et de traitement de cancers de l'ovaire
YU68900A (sh) Kombinacije inhibitora protein farnesiltransferaze i hmg coa reduktaze i njihova upotreba u tretmanu raka
AU2001270912A1 (en) Improvements relating to the security of authentication systems
WO2003035889A3 (fr) Compositions et procedes permettant de detecter des bacteries
AU2002220697A1 (en) Isolated luciferases lu164, lual and lu22, and the use of the same
WO2006015191A3 (fr) Analogues de lonidamine multicycliques
WO2001082972A3 (fr) Compositions comportant des vehicules et des complexes transportables

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002546708

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2430077

Country of ref document: CA

Ref document number: 2001289132

Country of ref document: AU

Ref document number: 1020037007054

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 01819673X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001968928

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001968928

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037007054

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001968928

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载